Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:03 AM ET 8-K
Bankruptcy & Restructuring Getty Images Holdings, Inc. GETYQ

Getty Images Holdings Bankruptcy & Restructuring

Getty Images entered into a restructuring support agreement (RSA) to implement a comprehensive recapitalization through a prepackaged Chapter 11 plan of reorganization. The deal includes a $533 million equity commitment from the Getty Family and Koch Equity Development, the retirement of senior unsecured notes for $170.2 million in cash, and the conversion of existing equity into 100% ownership for the majority shareholders, taking the company private.

Counterparty
The Getty Family and Koch Equity Development
6:42 AM ET
Earnings Call Ttm Technologies Inc TTMI ▶ Call

TTM Technologies Earnings Call: Key Takeaways

TTM Technologies delivered record Q2 2026 results, beating guidance and raising full-year revenue and EPS outlooks driven by massive AI data center demand and defense growth.

6:30 AM ET 8-K
Capital Raise Formfactor Inc FORM

Formfactor Capital Raise of $300M

FormFactor entered into a Securities Purchase Agreement with Teradyne, Inc. for a $300 million strategic equity investment via a private placement of 2,234,887 shares of common stock. The transaction is part of a broader technology collaboration aimed at accelerating semiconductor testing for AI, high-performance computing, and advanced packaging applications.

Value
$300M
Counterparty
Teradyne, Inc.
6:27 AM ET 8-K
Capital Raise ADC Therapeutics SA ADCT

ADC Therapeutics Capital Raise of $86.6M

ADC Therapeutics entered into securities purchase agreements for a $86.6 million private placement (PIPE) involving the sale of 12.9 million common shares and 48.1 million pre-funded warrants. The financing included participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. Proceeds will be used to fund ZYNLONTA pipeline studies and extend the company's cash runway into 2029.

Value
$86.6M
Counterparty
Bain Capital Life Sciences
6:20 AM ET
Earnings Call IonQ, Inc. IONQ ▶ Call

IonQ Earnings Call: Key Takeaways

IonQ delivered record Q2 revenue of $80.1M, up 287% YoY, while closing the $1.8B Skywater acquisition to become a vertically integrated quantum platform.

6:11 AM ET 8-K
Capacity Expansion Ttm Technologies Inc TTMI

Ttm Technologies Capacity Expansion: $400M Investment

TTM Technologies announced a $400 million incremental investment to expand manufacturing capacity across four facilities in China and its facility in Penang, Malaysia. The expansion uses a "rapid-ramp" brownfield approach to scale advanced interconnect technology for AI data center infrastructure and hyperscalers. This investment is in addition to the company's previously disclosed $1.2 billion commitment for the 2025-2029 period.

Value
$400M
Term
2025-2029
6:05 AM ET 8-K
Partnership Humana Inc HUM

Humana Partnership with BlackRock, Inc. Worth $2.8B

Humana entered into a new strategic joint venture with BlackRock to manage and operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake held by Welsh, Carson, Anderson & Stowe (WCAS) for approximately $2.8 billion, providing Humana with a lower cost of capital and enhanced balance sheet efficiency by removing existing put option liabilities.

Value
$2.8B
Counterparty
BlackRock, Inc.
Term
through 2033
6:03 AM ET 8-K
M&A Deal IonQ, Inc. IONQ

IonQ Signs $1.15B M&A Deal with Elisity, Inc.

IonQ has entered into a definitive agreement to acquire Elisity, Inc., a Zero Trust security company, in an all-stock transaction valued at up to $1.3 billion including earnouts. The deal consists of $1.15 billion in closing consideration plus up to $150 million in revenue-based earnout consideration through January 2028. The acquisition aims to combine IonQ's quantum cryptography capabilities with Elisity's Zero Trust platform to address emerging quantum-era cybersecurity threats.

Value
$1.15B
Counterparty
Elisity, Inc.

“With Elisity and its team as part of IonQ, we will be well positioned to help customers protect critical infrastructure and enterprise networks throughout the transition to the quantum era. As I said first, Q-Day is coming much faster than predicted. IonQ is offering its customers a vertically integrated full-stack quantum platform across quantum computing, networking, sensing and cybersecurity. Just as adding SkyWater Technology expanded IonQ’s capabilities in chip design, fabrication and packaging, Elisity will bring proven enterprise policy enforcement scale and deployment experience to our quantum security strategy and will give IonQ a strong growth platform to serve customers and create value for our shareholders.”

Niccolo de Masi, Chairman and CEO of IonQ

“Our customers need to prioritize post-quantum cryptography initiatives while securing existing assets to keep essential operations running. With IonQ, we will be optimally positioned to partner with them to modernize their crypto-agility programs, accelerate post-quantum cryptography capabilities while advancing their holistic Zero Trust posture and deploy hybrid-cybersecurity solutions today that are prepared for the quantum future.”

James Winebrenner, CEO of Elisity
6:03 AM ET 8-K
Clinical Trial Data Zenas BioPharma, Inc. ZBIO

Zenas BioPharma Clinical Trial Data

Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.

6:03 AM ET 8-K
Nasdaq/NYSE Compliance Notice Clearone Inc CLRO

Clearone Nasdaq/NYSE Compliance Notice

ClearOne, Inc. received a staff determination letter from Nasdaq on October 8, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders' equity requirement. As a result, Nasdaq has determined to delist the company's common stock, though ClearOne intends to appeal this decision before a Nasdaq Hearings Panel to stay the delisting process.

Counterparty
Nasdaq
6:02 AM ET 8-K
Nasdaq/NYSE Compliance Notice Quetta Acquisition Corp QETA

Quetta Acquisition Nasdaq/NYSE Compliance Notice

Quetta Acquisition Corporation received a delisting notice from Nasdaq because it failed to complete an initial business combination within the required 36-month period following its IPO. Trading of the company's securities (QETA, QETAR, QETAU) will be suspended on October 14, 2026, and the company expects its securities to transition to the OTC Pink Limited Market.

Counterparty
The Nasdaq Stock Market LLC
5:29 PM ET 8-K/A
M&A Deal Gentherm Inc THRM

Gentherm M&A Deal with Modine Manufacturing Company

Gentherm completed the acquisition of Modine Manufacturing Company's Performance Technologies business (SpinCo) through a merger transaction. Modine shareholders received 0.44619 shares of Gentherm common stock for each SpinCo share, resulting in Modine shareholders owning approximately 43.62% of the combined company. The deal establishes Gentherm as a scaled leader in thermal management and precision flow solutions.

Counterparty
Modine Manufacturing Company
5:26 PM ET 8-K
M&A Deal Gran Tierra Energy Inc. GTE

Gran Tierra Energy Signs $1.33B M&A Deal with Maurel & Prom

Gran Tierra Energy stockholders approved the sale of the company's Colombian and Ecuadorian businesses to Maurel & Prom for approximately $1.33 billion. The company expects to receive $315 million in net cash proceeds and become debt-free upon the deal's expected closing by December 31, 2026.

Value
$1.33B
Counterparty
Maurel & Prom
5:25 PM ET 8-K
Capital Raise Sunshine Biopharma Inc. SBFM

Sunshine Biopharma Capital Raise of $6M

Sunshine Biopharma Inc. closed a best efforts public offering of approximately 10.9 million units for gross proceeds of $6.0 million. Each unit, priced at $0.55, consists of one share of common stock (or a pre-funded warrant) and two Series D warrants. The company intends to use the net proceeds for general corporate purposes and working capital.

Value
$6M
Counterparty
Aegis Capital Corp.
5:21 PM ET 8-K
Capital Raise Flyte Aviation, Inc. VJET

Flyte Aviation Capital Raise of $2.05M

Flyte Aviation, Inc. entered into an agreement with existing investors to sell 2,050 shares of Series C-4 Convertible Preferred Stock for gross proceeds of $2.05 million. The preferred shares are convertible into common stock at a price of $1.00 per share. Additionally, the company reduced the conversion price of all outstanding Series C, Series D, and Series J preferred stock to $1.00 per share.

Value
$2.05M
5:21 PM ET 8-K
Nasdaq/NYSE Compliance Notice Streamex Corp. STEX

Streamex Nasdaq/NYSE Compliance Notice

Streamex Corp. received a deficiency notice from Nasdaq on October 7, 2026, for failing to maintain the minimum bid price of $1.00 per share over 30 consecutive business days. The company has until April 5, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least ten consecutive business days. The notice does not have an immediate effect on the listing of the company's common stock (STEX).

Counterparty
Nasdaq
Term
180 days
5:19 PM ET 8-K
Capital Raise Arrive AI Inc. ARAI

Arrive AI Capital Raise

Arrive AI Inc. closed a $250,000 private placement (PIPE) with an accredited investor, issuing 384,615 shares of common stock and warrants at a purchase price of $0.65 per unit. The investment was priced at a 213% premium to the company's recent trading price, and the investor expressed interest in evaluating up to $10 million in additional future financing.

5:16 PM ET 8-K
Nasdaq/NYSE Compliance Notice Artelo Biosciences, Inc. ARTL

Artelo Biosciences Nasdaq/NYSE Compliance Notice

Artelo Biosciences was identified as one of approximately 180 companies currently below Nasdaq's new $5 million minimum Market Value of Listed Securities (MVLS) requirement. While the rule is currently under a temporary stay and subject to proposed modifications, the company is monitoring the situation and considering potential actions to maintain compliance, such as capital raises or expense management.

Counterparty
Nasdaq
5:08 PM ET
Earnings Call Live Nation Entertainment, Inc. LYV ▶ Call

Live Nation Entertainment Earnings Call: Key Takeaways

Live Nation reports record demand with double-digit fan growth expected for 2026, driven by international expansion and a strong second-half concert slate.

5:05 PM ET 8-K
M&A Deal Vivakor, Inc. VIVK

Vivakor Signs $40M M&A Deal with Direct Midstream, LLC

Vivakor, Inc. has signed a non-binding Letter of Intent to acquire 100% of Direct Midstream, LLC for a gross purchase price of $40 million. The deal structure includes a $10 million capital investment by Vivakor, with the remaining consideration consisting of $29 million in Series B Preferred Stock and $1 million in common stock. The acquisition aims to expand Vivakor's Permian Basin infrastructure and oilfield waste management capabilities.

Value
$40M
Counterparty
Direct Midstream, LLC
5:03 PM ET 8-K
Capital Raise Crescent Energy Co CRGY

Crescent Energy Capital Raise of $1.15B

Crescent Energy Company priced an underwritten public offering of 80,000,000 shares of Class A Common Stock at $12.50 per share, with underwriters fully exercising their option for an additional 12,000,000 shares. The company expects to receive approximately $1,115.9 million in net proceeds, which will be used to fund the cash consideration for its acquisition of Eagle Ford assets from Devon Energy. KKR & Co. Inc. affiliates participated in the offering by purchasing 40,000,000 shares at the public offering price.

Value
$1.15B
Counterparty
J.P. Morgan Securities LLC
5:01 PM ET 8-K
Capital Raise Sintx Technologies, Inc. SINT

Sintx Technologies Capital Raise of $2.01M

SINTX Technologies received approximately $2.01 million in gross proceeds from the exercise of Class B Common Stock Purchase Warrants. The company issued 651,204 shares of common stock and 290,219 pre-funded warrants at an exercise price of $2.14 per share, while unexercised Class B warrants expired.

Value
$2.01M
5:00 PM ET 8-K
Nasdaq/NYSE Compliance Notice DarkPulse, Inc. DPLS

DarkPulse Nasdaq/NYSE Compliance Notice

DarkPulse, Inc. received notice that its common stock was removed from the OTCQB market and moved to the OTCID market effective October 8, 2026. The transition occurred because the company failed to maintain the minimum bid price requirement of $0.01 per share following the expiration of a grace period.

Counterparty
OTC Markets Group Inc.
4:55 PM ET 8-K
M&A Deal Selectis Health, Inc. GBCS

Selectis Health M&A Deal with Black Pearl Equities II, LLC

Selectis Health, Inc. completed its merger with Black Pearl Equities II, LLC, a subsidiary of Black Pearl Equities, LLC. Following a successful tender offer for approximately 90.93% of outstanding shares at $5.75 per share, the company merged with a subsidiary of the purchaser and became a wholly owned private subsidiary. The merger was effected under Utah law without a stockholder vote.

Counterparty
Black Pearl Equities II, LLC
4:31 PM ET 8-K
M&A Deal iSpecimen Inc. ISPC

iSpecimen M&A Deal with Foldlab AI Ltd.

iSpecimen Inc. stockholders approved the acquisition of assets from Foldlab AI Ltd., which includes the issuance of common stock as partial consideration. The company also received approval for potential future equity issuances exceeding 19.99% of outstanding shares under Nasdaq rules, while the vote on a proposed reverse stock split was adjourned to October 30, 2026.

Counterparty
Foldlab AI Ltd.
4:31 PM ET 8-K
Capital Raise bioAffinity Technologies, Inc. BIAF

bioAffinity Technologies Capital Raise of $4M

bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.

Value
$4M
Counterparty
institutional investor
4:31 PM ET 8-K
M&A Deal XMax Inc. XMAX

XMax Signs $4.12M M&A Deal with Hexa Creation Inc.

XMax Inc. entered into a definitive agreement to acquire 100% of Hexa Creation Inc. for approximately $4.12 million in cash. Hexa Creation is a developer of 1200V vertical gallium nitride (GaN) power semiconductor technology aimed at AI data center infrastructure. The deal expands XMax's strategic focus into high-voltage power semiconductors for AI computing and electric vehicles.

Value
$4.12M
Counterparty
Hexa Creation Inc.

“This acquisition marks XMax’s entry into high-voltage power semiconductors, a field closely tied to the growing power demands of AI infrastructure. The acquisition of Hexa Creation diversifies our business opportunities and complements XMax’s growing AI business as XMax builds out AI software, platform-based and GPU services through our wholly owned subsidiaries XMax AI Inc. and Elonx AI Holdings PTE. LTD.”

Andy Lu, Chief Executive Officer of XMax

“We believe the acquisition by XMax would give our 1200V vertical GaN work a path toward commercialization. We believe vertical GaN can bring higher efficiency and power density to high-voltage applications, and XMax’s support allows us to focus on advancing that technology.”

Professor Yuji Zhao, CEO and Founder of Hexa Creation
4:31 PM ET 8-K
M&A Deal Hepion Pharmaceuticals, Inc. HEPA

Hepion Pharmaceuticals Signs $4.38M M&A Deal with Gravitas Life Sciences, LLC

Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.

Value
$4.38M
Counterparty
Gravitas Life Sciences, LLC
4:31 PM ET 8-K
M&A Deal Alpine Income Property Trust, Inc. PINE

Alpine Income Property Trust Signs $117M M&A Deal with institutional owner

Alpine Income Property Trust, Inc. entered into a definitive agreement to acquire a 13-property industrial portfolio across 11 states for $117.3 million. The company has made a $1.0 million non-refundable earnest money deposit and expects the closing of the acquisition to be probable.

Value
$117M
Counterparty
institutional owner
4:30 PM ET 8-K
Nasdaq/NYSE Compliance Notice Alaunos Therapeutics, Inc. TCRT

Alaunos Therapeutics Nasdaq/NYSE Compliance Notice

Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting and is currently evaluating strategic alternatives to regain compliance.

Counterparty
The Nasdaq Stock Market LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.